公开(公告)号：EP1440052A1

公开(公告)日：2004-07-28

申请号：EP02787530.1

申请日：2002-10-30

申请人： SMITHKLINE BEECHAM PLC

发明人： CHAN, Wai, Ngor,GlaxoSmithKline ,  JOHNS, Amanda,GlaxoSmithKline ,  PORTER, Roderick, A.,GlaxoSmithKline ,  STEAD, Rachel, E. A.,GlaxoSmithKline ,  VIMAL, Mythily,GlaxoSmithKline

IPC分类号： C07C233/73 ,  C07C233/77 ,  C07C233/87 ,  C07C235/46 ,  C07D271/02 ,  C07D319/08 ,  A61K31/165 ,  A61K31/33 ,  A61P3/00

CPC分类号： C07D271/06 ,  C07C233/73 ,  C07C233/77 ,  C07C233/87 ,  C07C235/46 ,  C07C235/84 ,  C07C255/57 ,  C07C2603/18 ,  C07D215/48 ,  C07D215/50 ,  C07D217/26 ,  C07D231/14 ,  C07D249/06 ,  C07D277/56 ,  C07D307/79 ,  C07D317/68

摘要： This invention relates to certain benzamide derivatives and their use as pharmaceuticals.

公开(公告)号：EP1399441A1

公开(公告)日：2004-03-24

申请号：EP02754750.4

申请日：2002-06-25

申请人： SMITHKLINE BEECHAM PLC

发明人： BRANCH, Clive, Leslie,GlaxoSmithKline ,  CHAN, Wai, Ngor,GlaxoSmithKline ,  JOHNS, Amanda,GlaxoSmithKline ,  JOHNSON, Christopher, Norbert,GlaxoSmithKline ,  NASH, David, John,GlaxoSmithKline ,  NOVELLI, Riccardo,GlaxoSmithKline ,  PILLEUX, Jean-Pierre,GlaxoSmithKline ,  PORTER, Roderick, Alan,GlaxoSmithKline ,  STEAD, Rachel, Elizabeth, Anne,GlaxoSmithKline ,  STEMP, Geoffrey,GlaxoSmithKline

IPC分类号： C07D417/14 ,  C07D411/14 ,  C07D407/14 ,  C07D413/14 ,  A61K31/445 ,  A61P25/00 ,  A61P3/10 ,  A61P15/00 ,  C07D407/06 ,  C07D491/04 ,  C07D401/06 ,  C07D409/14 ,  C07D471/04

CPC分类号： C07D417/14 ,  C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/06 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D491/04

摘要： This invention relates to N-aroyl cyclic amine derivatives of formula (I), wherein X represents a bond, oxygen , NR3 or a group (CH¿2?), wherein n represents 1, 2 or 3; Y represents CH2, CO, CH(OH), or CH2CH(OH); Het is an optionally substituted bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; Ar?2¿ represents an optionally substituted phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S and their use as pharmaceuticals, specifically as orexin receptor antagonists.